Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens NPH Knudsen, A Olsen, C Buonsanti, F Follmann, Y Zhang, RN Coler, ... Scientific reports 6 (1), 19570, 2016 | 256 | 2016 |
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA J Holmgren, J Adamsson, F Anjuère, J Clemens, C Czerkinsky, ... Immunology letters 97 (2), 181-188, 2005 | 240 | 2005 |
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens F Wegmann, KH Gartlan, AM Harandi, SA Brinckmann, M Coccia, ... Nature biotechnology 30 (9), 883-888, 2012 | 227 | 2012 |
A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection AM Harandi, K Eriksson, J Holmgren Journal of virology 77 (2), 953-962, 2003 | 218 | 2003 |
Differential roles of B cells and IFN-γ-secreting CD4+ T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice AM Harandi, B Svennerholm, J Holmgren, K Eriksson Journal of General Virology 82 (4), 845-853, 2001 | 167 | 2001 |
Vaccine adjuvants: a priority for vaccine research AM Harandi, D Medaglini, RJ Shattock, WG convened by EUROPRISE Vaccine 28 (12), 2363-2366, 2010 | 139 | 2010 |
Vaccine adjuvants: scientific challenges and strategic initiatives AM Harandi, G Davies, OF Olesen Expert review of vaccines 8 (3), 293-298, 2009 | 117 | 2009 |
Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of … AM Harandi, B Svennerholm, J Holmgren, K Eriksson Journal of Virology 75 (14), 6705-6709, 2001 | 115 | 2001 |
The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection M Lindqvist, J Persson, K Thörn, AM Harandi The Journal of Immunology 182 (10), 6435-6443, 2009 | 93 | 2009 |
Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells NR Mathew, JK Jayanthan, IV Smirnov, JL Robinson, H Axelsson, ... Cell reports 35 (12), 2021 | 92 | 2021 |
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study A Huttner, ST Agnandji, C Combescure, JF Fernandes, EB Bache, ... The Lancet Infectious Diseases 18 (7), 738-748, 2018 | 89 | 2018 |
Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 … S Tengvall, A Lundqvist, RJ Eisenberg, GH Cohen, AM Harandi Journal of virology 80 (11), 5283-5291, 2006 | 86 | 2006 |
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA J Holmgren, AM Harandi, C Czerkinsky Expert review of vaccines 2 (2), 205-217, 2003 | 84 | 2003 |
Molecular signatures of vaccine adjuvants T Olafsdottir, M Lindqvist, AM Harandi Vaccine 33 (40), 5302-5307, 2015 | 78 | 2015 |
Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of … S Raghavan, J Nystrom, M Fredriksson, J Holmgren, AM Harandi Infection and immunity 71 (12), 7014-7022, 2003 | 76 | 2003 |
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa A Huttner, C Combescure, S Grillet, MC Haks, E Quinten, C Modoux, ... Science translational medicine 9 (385), eaaj1701, 2017 | 64 | 2017 |
Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice J Del Campo, M Lindqvist, M Cuello, M Bäckström, O Cabrerra, J Persson, ... Vaccine 28 (5), 1193-1200, 2010 | 64 | 2010 |
CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. AM Harandi, J Holmgren Current opinion in investigational drugs (London, England: 2000) 5 (2), 141-145, 2004 | 63 | 2004 |
Comparative systems analyses reveal molecular signatures of clinically tested vaccine adjuvants TA Olafsdottir, M Lindqvist, I Nookaew, P Andersen, J Maertzdorf, ... Scientific reports 6 (1), 39097, 2016 | 59 | 2016 |
Immunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research priorities D Boraschi, M Abebe Alemayehu, A Aseffa, F Chiodi, J Chisi, G Del Prete, ... PLoS Neglected Tropical Diseases 2 (6), e255, 2008 | 58 | 2008 |